Page 23 - Read Online
P. 23
Arroyo Seguí et al. J Transl Genet Genom 2020;4:263-77 I http://dx.doi.org/10.20517/jtgg.2020.35 Page 273
OPRM1 rs1799971: Level 3 OPRD1 rs2234918: Level 3 COMT rs4680: Level 3 ARRB2 rs1045280: Level 3 ABCB1 rs1045642: Not available OPRD1 rs678849: Level 2B OPRD1 rs581111: Level 3 OPRD1 rs529520: Level 3 Other variants: not available
[46,68] [48] [49]
No associations were found between any variant and program response For OPRM1 rs1799971, a significant association was found, where carriers of the G-allele (AG/ GG) required higher MEDD for analgesic control and prevention of withdrawal symptoms For OPRM1 rs1799971, AA genotype was associated with a higher incidence of nausea and gastrointestinal adverse events when compared with AG/GG genotypes For OPRD1 rs2234918, CT genotype was associated with
rs1799971 rs2234918 rs4680 rs1045280 rs1045642 rs678849 rs581111 rs529520 rs1042114 rs678849 rs10753331 rs2234918
OPRM1 OPRD1 COMT ARRB2 ABCB1 OPRD1 OPRD1
Response to opioid deprescription program 3 , incidence of adverse effects Urine drug screens for opioids Urine drug screens for opioids
European ancestry (n = 88, 64% females) African American (n = 55, 84% males) European American Males (n = 218) vs. Females (n = 81) (Subset of START trial)
